ClinicalTrials.gg
CompletedNCT00943124Updated Jun 19, 2015Results posted

MK0524B Bioequivalence Study (0524B-070)

A Phase 1 interventional study of MK0524B (ER niacin (+) laropiprant (+) simvastatin) and MK0524A (ER niacin + laropiprant) in Dyslipidemia, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-06-19.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies in Dyslipidemias by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Dyslipidemias · Merck & Co., Inc.

Enrollment
11th of 24
220 · median 190
Started
2007
with 2 others
Phase 1
9 of 26
none open now
Registered
11th of 26
by date

Among the 26 studies in Dyslipidemias by Merck & Co., Inc, this one is the 11th largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2007, is one of 9 in phase 1, and was the 11th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

None of the 26 studies in Dyslipidemias by Merck & Co., Inc is open now. The open studies under Dyslipidemias, anywhere →

Where they have run

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies in Dyslipidemias by Merck & Co., Inc as a file.
02

Study summary

This study will evaluate:

  1. the bioequivalence of simvastatin and simvastatin acid following dose of simvastatin (ZOCOR™) given together with one tablet of MK0524A or as a component of the triple combination tablet MK0524B.
  2. the bioequivalence of laropiprant and ER niacin when administered as the triple combination tablet MK0524B or as the double combination tablet MK0524A given together with simvastatin.
03

Conditions studied

  • Dyslipidemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is in good health
  • Subject is a nonsmoker
  • Subject is willing to follow the study guidelines

Exclusion criteria

Exclusion Criteria:

  • Subject has or has a history of any illness that might confound the results of the study or make participation in the study unsafe for the subject
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
220 participants (actual)

Study arms

  • Experimental
    MK0524B then Simvastatin + MK0524A

    Period 1: 1 tablet of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg). Period 2: 1 tablet of simvastatin 20 mg (Zocor™) and 1 tablet of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) as separate tablets.

    Drug: MK0524B (ER niacin (+) laropiprant (+) simvastatin) · Drug: MK0524A (ER niacin + laropiprant) · Drug: Simvastatin

  • Experimental
    Simvastatin + MK0524A then MK0524B

    Period 1: 1 tablet of simvastatin 20 mg (Zocor™) and 1 tablet of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) as separate tablets. Period 2: 1 tablet of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg).

    Drug: MK0524B (ER niacin (+) laropiprant (+) simvastatin) · Drug: MK0524A (ER niacin + laropiprant) · Drug: Simvastatin

Interventions

  • DrugMK0524B (ER niacin (+) laropiprant (+) simvastatin)

    Drug page: MK-0524B

    Single dose of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg) in one of two treatment periods.

    Also known as: MK0524B

  • DrugMK0524A (ER niacin + laropiprant)

    Drug page: MK-0524A

    Single dose of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) in one of two treatment periods.

    Also known as: MK0524A

  • Single dose simvastatin (Zocor™) 20 mg in one of two treatment periods.

    Also known as: Zocor™

06

What researchers measure

Primary outcomes

  1. Plasma Area Under the Curve (AUC(0 to 48hr)) for Simvastatin Acid

    Plasma Area Under the Curve of simvastatin acid, the active metabolite of simvastatin

    Time frame: Through 48 Hours Post Dose

  2. Peak Plasma Concentration (Cmax) of Simvastatin Acid

    Peak Plasma Concentration (Cmax) for Simvastatin Acid, the active metabolite of simvastatin

    Time frame: 48 Hours Post Dose

  3. Plasma Area Under the Curve (AUC(0 to 48 Hour)) for Simvastatin

    Plasma Area Under the Curve of simvastatin

    Time frame: Through 48 Hours Post Dose

  4. Peak Plasma Concentration (Cmax) of Simvastatin

    Time frame: 48 Hours Post Dose

  5. Plasma Area Under the Curve (AUC(0 to Infinity)) for Laropiprant

    Plasma Area Under the Curve of Laropiprant

    Time frame: 48 Hours Post Dose

  6. Peak Plasma Concentration (Cmax) of Laropiprant

    Time frame: 48 Hours Post Dose

  7. Peak Plasma Concentration (Cmax) of Nicotinuric Acid

    Peak Plasma Concentration (Cmax) for Nicotinuric Acid, one of the active metabolites of Niacin

    Time frame: 24 Hours Post Dose

  8. Total Urinary Excretion of Niacin and Its Metabolites

    Time frame: 96 Hours Post Dose

07

Results

Posted Jan 6, 2010

Participant flow

Period 1
Participant flow — Period 1
MilestoneMK0524B Then Simvastatin + MK0524ASimvastatin + MK0524A Then MK0524B
Started110110
Completed108108
Not completed22
Withdrew: Withdrawal by subject11
Withdrew: Did not follow study procedures10
Withdrew: Personal reasons01
Period 2
Participant flow — Period 2
MilestoneMK0524B Then Simvastatin + MK0524ASimvastatin + MK0524A Then MK0524B
Started108108
Completed108108
Not completed00

Outcome measures

PrimaryPlasma Area Under the Curve (AUC(0 to 48hr)) for Simvastatin Acid

Plasma Area Under the Curve of simvastatin acid, the active metabolite of simvastatin

Time frame:
Through 48 Hours Post Dose
Reported as:
Least squares mean · ng/mL * Hour
Plasma Area Under the Curve (AUC(0 to 48hr)) for Simvastatin Acid
ng/mL * HourMK0524BSimvastatin + MK0524A
Plasma Area Under the Curve (AUC(0 to 48hr)) for Simvastatin Acid9.19 ± 8.388.03 ± 7.78
Statistical analysis
  • MK0524B vs Simvastatin + MK0524A · Least-squares mean ratio: 1.14 · 90% CI 1.09 to 1.20
PrimaryPeak Plasma Concentration (Cmax) of Simvastatin Acid

Peak Plasma Concentration (Cmax) for Simvastatin Acid, the active metabolite of simvastatin

Time frame:
48 Hours Post Dose
Reported as:
Least squares mean · ng/mL
Peak Plasma Concentration (Cmax) of Simvastatin Acid
ng/mLMK0524BSimvastatin + MK0524A
Peak Plasma Concentration (Cmax) of Simvastatin Acid1.016 ± 0.9460.918 ± 0.906
Statistical analysis
  • MK0524B vs Simvastatin + MK0524A · Least-squares mean ratio: 1.11 · 90% CI 1.05 to 1.16
PrimaryPlasma Area Under the Curve (AUC(0 to 48 Hour)) for Simvastatin

Plasma Area Under the Curve of simvastatin

Time frame:
Through 48 Hours Post Dose
Reported as:
Least squares mean · ng/mL * Hour
Plasma Area Under the Curve (AUC(0 to 48 Hour)) for Simvastatin
ng/mL * HourMK0524BSimvastatin + MK0524A
Plasma Area Under the Curve (AUC(0 to 48 Hour)) for Simvastatin15.03 ± 9.8815.56 ± 9.11
Statistical analysis
  • MK0524B vs Simvastatin + MK0524A · Least-squares mean ratio: 0.97 · 90% CI 0.93 to 1.00
PrimaryPeak Plasma Concentration (Cmax) of Simvastatin
Time frame:
48 Hours Post Dose
Reported as:
Least squares mean · ng/mL
Peak Plasma Concentration (Cmax) of Simvastatin
ng/mLMK0524BSimvastatin + MK0524A
Peak Plasma Concentration (Cmax) of Simvastatin5.81 ± 4.316.33 ± 4.64
Statistical analysis
  • MK0524B vs Simvastatin + MK0524A · Least-squares mean ratio: 0.92 · 90% CI 0.87 to 0.97
PrimaryPlasma Area Under the Curve (AUC(0 to Infinity)) for Laropiprant

Plasma Area Under the Curve of Laropiprant

Time frame:
48 Hours Post Dose
Reported as:
Least squares mean · nmol/L * hour
Plasma Area Under the Curve (AUC(0 to Infinity)) for Laropiprant
nmol/L * hourMK0524BSimvastatin + MK0524A
Plasma Area Under the Curve (AUC(0 to Infinity)) for Laropiprant5486 ± 28325405 ± 2618
Statistical analysis
  • MK0524B vs Simvastatin + MK0524A · Least-squares mean ratio: 1.02 · 90% CI 0.99 to 1.04
PrimaryPeak Plasma Concentration (Cmax) of Laropiprant
Time frame:
48 Hours Post Dose
Reported as:
Least squares mean · nmol/L
Peak Plasma Concentration (Cmax) of Laropiprant
nmol/LMK0524BSimvastatin + MK0524A
Peak Plasma Concentration (Cmax) of Laropiprant1030 ± 642953 ± 542
Statistical analysis
  • MK0524B vs Simvastatin + MK0524A · Least-squares mean ratio: 1.08 · 90% CI 1.02 to 1.14
PrimaryPeak Plasma Concentration (Cmax) of Nicotinuric Acid

Peak Plasma Concentration (Cmax) for Nicotinuric Acid, one of the active metabolites of Niacin

Time frame:
24 Hours Post Dose
Reported as:
Least squares mean · ng/mL
Peak Plasma Concentration (Cmax) of Nicotinuric Acid
ng/mLMK0524BSimvastatin + MK0524A
Peak Plasma Concentration (Cmax) of Nicotinuric Acid620 ± 536807 ± 469
Statistical analysis
  • MK0524B vs Simvastatin + MK0524A · Least-squares mean ratio: 0.77 · 90% CI 0.72 to 0.82
PrimaryTotal Urinary Excretion of Niacin and Its Metabolites
Time frame:
96 Hours Post Dose
Reported as:
Least squares mean · µmol
Total Urinary Excretion of Niacin and Its Metabolites
µmolMK0524BSimvastatin + MK0524A
Total Urinary Excretion of Niacin and Its Metabolites5339 ± 9685825 ± 1188
Statistical analysis
  • MK0524B vs Simvastatin + MK0524A · Least-squares mean ratio: 0.92 · 90% CI 0.89 to 0.94

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MK0524B—0/220 (0%)61/220 (27.7%)
Simvastatin + MK0524A—0/220 (0%)58/220 (26.4%)
Most frequent other events
Showing 10 of 59
Most frequent other events
EventMK0524BSimvastatin + MK0524A
HeadacheNervous system disorders9/22017/220
FlushingVascular disorders8/22017/220
NauseaGastrointestinal disorders15/22012/220
Abdominal PainGastrointestinal disorders7/2203/220
PruritusSkin and subcutaneous tissue disorders7/2203/220
ConstipationGastrointestinal disorders6/2202/220
VomitingGastrointestinal disorders3/2205/220
DiarrhoeaGastrointestinal disorders4/2202/220
Back PainMusculoskeletal and connective tissue disorders4/2200/220
ParaesthesiaNervous system disorders4/2203/220

Baseline characteristics

Age, Continuous
Age, Continuous(years)Overall Study Population
Mean35.11 (18 to 65)
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study Population
Female92
Male128
Height
Height(Centimeters)Overall Study Population
Mean169.58 (147 to 193)
Weight
Weight(Kilograms)Overall Study Population
Mean72.99 (43.6 to 111.2)
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of Aug 2007 and a completion of Aug 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2009
First posted
Jul 22, 2009
Start
Jul 2007
Primary completionActual
Aug 2007
CompletionActual
Aug 2007
Results first posted
Jan 6, 2010
Last update
Jun 19, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 19, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00943124
Responsible party
Sponsor
First posted
Jul 22, 2009
Start date
Jul 2007
Primary completion
Aug 2007
Completion
Aug 2007
Results posted
Jan 6, 2010
Last update
Jun 19, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: MK-0524B · MK-0524A · Simvastatin

Start the discussion